Abstract
Adriamycin (ADR) inhibits the carnitine palmitoyl transferase (CPT) system and consequently the transport of long-chain fatty acids across mitochondrial membranes. l-Carnitine (CARN) plays a major role in fatty acid oxidation by translocating activated long-chain fatty acids into the matrix of mitochondria. CARN has been shown to be of benefit in certain cardiac conditions including cardiomyopathy and myocardial infarction. This study was devised to investigate the effect of CARN on altered CPT I and CPT II activity in the cardiomyopathy associated with ADR therapy. We also assessed the effect of CARN on the plasma free, total, and acylcarnitine concentrations. Four groups, each consisting of four male Sprague-Dawley rats, were studied: group 1(n = 4) was not given either ADR or CARN; group 2 (n = 4) was given ADR (15 and 20 mg/kg, respectively, cumulative dose) by i.p. injections for 1 and 2 wk; group 3 (n = 4) was given the same dose of ADR with CARN (200 mg/kg); and group 4 (n = 4) was given CARN (200 mg/kg). The activities of CPT I and CPT II in heart were significantly decreased in the ADR-treated rats (p < 0.05) in a dose-dependent manner. The reduced activities of CPT I and CPT II, inhibited by ADR, were not normalized by supplementation with CARN (p < 0.05). In rats supplemented with CARN alone, the activities of CPT I and CPT II were elevated approximately 50% above those of the control rats (p < 0.05). ADR treatment resulted in elevation of plasma free and total CARN concentrations (p < 0.05). Supplementation with CARN did not effect the increased plasma CARN concentrations resulting from ADR treatment (p < 0.05). This study supports the concept that ADR toxicity results from the inhibition of both CPT I and CPT II activities and that one of the causes of ADR-induced cardiomyopathy is a result of globally impaired fatty acid oxidation.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- ADR:
-
adriamycin
- CARN:
-
l-carnitine
- CPT:
-
carnitine palmitoyltransferase
References
Singal PK, Siveski-Iliskovic N, Hill M, Thomas PT, Li T 1995 Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 27: 1055–1063
Link G, Tirosh R, Pinson A, Hershko C 1996 Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 27: 272–278
Doroshow JH 1983 Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43: 460–472
Rajagopalan S, Politi PM, Sinha BK, Meyers CE 1988 Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 48: 4766–4769
Mimnaugh EG, Trush MA, Gram TE 1983 Enhancement of rat heart microsomal lipid peroxidation following doxorubicin treatment in vivo. Cancer Treat Rep 67: 731–733
Lampidis TJ, Johnson LV, Israel M 1981 Effects of adriamycin on rat heart cells in culture: increased accumulation and nucleoli fragmentation in cardiac muscle v. non-muscle cells. J Mol Cell Cardiol 13: 913–924
Torti SV, Akimoto H, Lin K, Billingham ME, Torti FM 1998 Selective inhibition of muscle gene expression by oxidative stress in cardiac cells. J Mol Cell Cardiol 30: 1173–1180
Arai M, Tomaru K, Takizaua T, Sekiguchi K, Yokoyama T, Suzuki T, Nagai R 1998 Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubucin in rabbits. J Mol Cell Cardiol 30: 243–254
Iliskovic N, Singal PK 1997 Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am J Pathol 150: 727–734
Abdel-aleem S, El-Merzabani MM, Sayed-Ahmed M, Taylor DA, Lowe JE 1997 Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol 29: 789–797
Iliskovic N, Li T, Khaper N, Palace V, Singal PK 1998 Modulation of adriamycin-induced changes in serum free fatty acids, albumin and cardiac oxidative stress. Mol Cell Biochem 188: 161–166
Bordoni A, Baigi PL, Hrelia S 1999 The impairment of essential fatty acid metabolism as a key factor in doxorubicin-induced damage in cultured rat cardiomyocytes. Biochim Biophys Acta 1440: 100–106
Sayed-Ahmed MM, Sharawy S, Shouman SA, Osman AM 1999 Reversal of doxorubicin-induced cardiac metabolic damage byl-carnitine. Phamacol Res 39: 289–295
Hong YM, Kim HS, Yoon HR 2002 Serum lipid and fatty acid profiles in adriamycin-induced cardiomyopathy after administration ofl-carnitine. Pediatr Res 51: 249–255
Bressler R, Gay R, Copeland JG, Bahl JJ, Bedotto J, Goldman S 1989 Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction. Life Sci 44: 1897–1906
Corr PB, Gross RW, Sobel BE 1984 Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Circ Res 55: 135–154
Brady LJ, Brady PS 1987 Hepatic and cardiac carnitine palmitoyltransferase activity: effects of adriamycin and galactosamine. Biochem Pharmacol 36: 3419–3423
Kashfi K, Israel M, Sweatman TW, Seshadri R, Cook GA 1990 Inhibition of mitochondrial carnitine palmitoyltransferases by adriamycin and adriamycin analogues. Biochem Pharmacol 40: 1441–1448
Hong YM, Kim SS 1998 The role of apoptosis in adriamycin induced cardiotoxicity and preventive effect ofl-carnitine in rat. J Korean Pediatr Soc 41: 760–768
Esser V, Brown NF, Cowan AT, Foster DW, McGarry JD 1996 Expression of a cDNA isolated from rat brown adipose tissue and heart identifies the product as the muscle isoform of carnitine palmitoyltransferase I (M-CPT I). J Biol Chem 271: 6972–6977
Lowry OH, Rosebrough NJ, Farr A, Randall RJ 1951 Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275
Takahashi M, Ueda S, Misaki H, Sugiyama N, Matsumoto K, Matsuo N, Murao S 1994 Carnitine determination by an enzymatic cycling method with carnitine dehydrogenase. Clin Chem 40: 817–821
Winter SC, Bruist NRM 2000 The role of energy metabolism defects in cardiomyopathy: from inborn errors to ischemia—cardiomyopathy in childhood, mitochondrial dysfunction, and the role ofl-carnitine. Am Heart J 139: 63–69
Treem WR, Stanley CA, Finegold DN, Hale DE, Coates PM 1988 Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. N Engl J Med 319: 1331–1336
Winter SC, Szabo-Aczel S, Curry CJR, Hutchinson HT, Hogue R, Shug AL 1987 Plasma carnitine deficiency: clinical observations in 51 pediatric patients. Am J Dis Child 141: 660–665
Regitz V, Shug AL, Fleck E 1990 Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart disease. Am J Cardiol 65: 755–760
Kawasaki N, Lee JD, Shimizu H, Ishii Y, Ueda T 1996 Cardiac energy metabolism stages of adriamycin-induced heart failure in rats. Int J Cardiol 55: 217–225
Waber LJ, Valle D, Neill C, DiMauro S, Shug A 1982 Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J Pediatr 101: 700–708
Strauss M, Anselmi G, Hermoso T, Tejero F 1998 Carnitine promotes heat shock protein synthesis in adriamycin-induced cardiomyopathy in a neonatal rat experimental model. J Mol Cell Cardiol 30: 2319–2325
Millington DS, Roe CR, Maltby DA 1984 Application of high resolution fast atom bombardment and constant B/E ratio linked scanning to the identification and analysis of acylcarnitines in metabolic disease. Biomed Mass Spectrom 11: 236–241
Millington DS, Bohan TP, Roe CR, Yergey AL, Liberato DJ 1985 Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry. Clin Chim Acta 15: 69–76
Vickers S, Duncan CA, White SD, Ramjit HG, Smith JL, Walker RW, Flynn H, Arison BH 1985 Carnitine and glucuronic acid conjugates of pivalic acid. Xenobiotica 15: 453–458
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported in part by a grant from the Ministry of Public Health and Welfare, South Korea (HMP-00-B-21000-0033 and HMP-98-E-1-0004).
Rights and permissions
About this article
Cite this article
Yoon, HR., Hong, Y., Boriack, R. et al. Effect of L-Carnitine Supplementation on Cardiac Carnitine Palmitoyltransferase Activities and Plasma Carnitine Concentrations in Adriamycin-Treated Rats. Pediatr Res 53, 788–792 (2003). https://doi.org/10.1203/01.PDR.0000057988.62605.13
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/01.PDR.0000057988.62605.13
This article is cited by
-
Carnitine Supplementation Attenuates Sunitinib-Induced Inhibition of AMP-Activated Protein Kinase Downstream Signals in Cardiac Tissues
Cardiovascular Toxicology (2019)
-
Inhibition of Gene Expression of Carnitine Palmitoyltransferase I and Heart Fatty Acid Binding Protein in Cyclophosphamide and Ifosfamide-Induced Acute Cardiotoxic Rat Models
Cardiovascular Toxicology (2014)
-
Carnitine and acylcarnitine profiles in dried blood spots of patients with acute myocardial infarction
Metabolomics (2013)
-
Effects of doxorubicin-containing chemotherapy and a combination with l-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma
Journal of Cancer Research and Clinical Oncology (2006)
